Education
About Us
Working with TipRanks
Follow Us
Cantargia AB (SE:CANTA)
:CANTA
CANTA Stock Chart & Stats
kr2.42
-kr0.02(-1.25%)
At close: 4:00 PM EST
kr2.42
-kr0.02(-1.25%)
Day’s Range― - ―
52-Week Rangekr1.00 - kr4.78
Previous CloseN/A
Volume611.88K
Average Volume (3M)1.42M
Market Cap
kr592.94M
Enterprise Valuekr276.13M
Total Cash (Recent Filing)kr81.88M
Total Debt (Recent Filing)kr22.39M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Nov 19, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding248,611,650
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.67
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cantargia AB News
CANTA FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.00 and its highest was kr4.78 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is kr592.94M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Nov 19, 2025 which is in 18 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Aug 21, 2025. The company reported -kr0.16 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.16.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Overvalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.17.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of -kr0.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.61%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in SE:CANTA
Company Description
Cantargia AB
Cantargia AB (CANTA) is a biotechnology company based in Sweden, focusing on the research and development of antibody-based treatments for various cancer types and autoimmune diseases. The company utilizes its proprietary technology platform to develop innovative therapies targeting specific molecular pathways involved in disease progression. Cantargia's lead product candidate, nadunolimab (CAN04), is an antibody therapy currently undergoing clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Guard Therapeutics International AB
―
Immunicum AB
―